Celon Pharma S.A. (CLN.WA)
PLN 23.85
(-7.38%)
PLN 23.85
(-7.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.24 Million PLN | 21.57% |
| 2022 | -34.73 Million PLN | -154.17% |
| 2021 | -13.66 Million PLN | -137.12% |
| 2020 | 36.81 Million PLN | 433.74% |
| 2019 | 6.89 Million PLN | -80.63% |
| 2018 | 35.61 Million PLN | 37.01% |
| 2017 | 25.99 Million PLN | -44.77% |
| 2016 | 47.05 Million PLN | -0.3% |
| 2015 | 47.19 Million PLN | 61.58% |
| 2014 | 29.21 Million PLN | 32.98% |
| 2013 | 21.96 Million PLN | 848.87% |
| 2012 | 2.31 Million PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -21.82 Million PLN | -135.31% |
| 2024 Q2 | -6.81 Million PLN | 68.76% |
| 2023 Q3 | -9.76 Million PLN | -185.55% |
| 2023 Q1 | -13.89 Million PLN | -299.83% |
| 2023 FY | -27.24 Million PLN | 21.57% |
| 2023 Q2 | 11.41 Million PLN | 182.2% |
| 2023 Q4 | -9.27 Million PLN | 5.04% |
| 2022 Q2 | -7.91 Million PLN | 28.52% |
| 2022 Q1 | -11.07 Million PLN | -84.88% |
| 2022 FY | -34.73 Million PLN | -154.17% |
| 2022 Q4 | -3.47 Million PLN | 68.56% |
| 2022 Q3 | -11.05 Million PLN | -39.54% |
| 2021 Q3 | -6.37 Million PLN | -516.95% |
| 2021 FY | -13.66 Million PLN | -137.12% |
| 2021 Q4 | -5.99 Million PLN | 5.95% |
| 2021 Q1 | 382 Thousand PLN | 155.63% |
| 2021 Q2 | 1.52 Million PLN | 300.0% |
| 2020 Q2 | 4.09 Million PLN | -57.49% |
| 2020 Q1 | 9.63 Million PLN | 938.15% |
| 2020 Q4 | 149.43 Thousand PLN | -92.17% |
| 2020 FY | 36.81 Million PLN | 433.74% |
| 2020 Q3 | 1.9 Million PLN | -53.4% |
| 2019 Q3 | 1.61 Million PLN | 754.08% |
| 2019 Q1 | 6.67 Million PLN | -34.83% |
| 2019 Q2 | -247.07 Thousand PLN | -103.7% |
| 2019 FY | 6.89 Million PLN | -80.63% |
| 2019 Q4 | -1.14 Million PLN | -171.16% |
| 2018 Q3 | 8.08 Million PLN | -12.27% |
| 2018 Q2 | 9.21 Million PLN | 14.24% |
| 2018 Q1 | 8.06 Million PLN | -9.83% |
| 2018 Q4 | 10.24 Million PLN | 26.78% |
| 2018 FY | 35.61 Million PLN | 37.01% |
| 2017 Q4 | 8.94 Million PLN | 110.87% |
| 2017 Q3 | 4.24 Million PLN | -44.99% |
| 2017 FY | 25.99 Million PLN | -44.77% |
| 2017 Q2 | 7.71 Million PLN | 51.41% |
| 2017 Q1 | 5.09 Million PLN | -16.48% |
| 2016 Q2 | 8.94 Million PLN | -53.45% |
| 2016 FY | 47.05 Million PLN | -0.3% |
| 2016 Q4 | 6.09 Million PLN | -30.76% |
| 2016 Q1 | 19.21 Million PLN | -29.23% |
| 2016 Q3 | 8.8 Million PLN | -1.57% |
| 2015 Q4 | 27.15 Million PLN | 551.98% |
| 2015 FY | 47.19 Million PLN | 61.58% |
| 2015 Q3 | 4.16 Million PLN | 0.0% |
| 2014 FY | 29.21 Million PLN | 32.98% |
| 2013 FY | 21.96 Million PLN | 848.87% |
| 2012 FY | 2.31 Million PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|